Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture
- PMID: 1618703
- PMCID: PMC5918847
- DOI: 10.1111/j.1349-7006.1992.tb01961.x
Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture
Abstract
The combination effect of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, and cisplatin (CDDP) was compared with that of vindesine (VDS) and CDDP using human lung adenocarcinoma PC-12 cells. The growth-inhibitory activity of NVB or VDS was time-dependent, whereas that of CDDP was AUC (area under the curve)-dependent. When NVB or VDS was used in combination with CDDP simultaneously for 24 h, antagonism was observed in terms of growth-inhibitory activity. However, additive combination effect was observed when NVB or VDS treatment was followed by CDDP treatment. On this treatment schedule, a synergistic combination effect was observed in terms of the cell-killing activity assessed by colony formation assay. The growth-inhibitory activity of NVB or VDS was detected 24 h after the treatment, whereas that of CDDP became significant 72 h after the treatment. NVB and VDS caused cell accumulation in G2M phase at 10 times their IC80 values, and cells with less than diploid DNA content were detected after 24 h at IC80. CDDP caused accumulation of cells in S phase, and the effect became detectable 16 h after the treatment. The DNA histogram of cells treated with NVB or VDS in combination with CDDP was a superposition of those of cells treated with each drug alone. Significant differences in the characteristics of anticellular activity were not detected between NVB and VDS, although NVB inhibited cell growth at a slightly lower concentration than VDS at the short exposure time of 1-8 h.
Similar articles
-
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].Bull Cancer. 1996 May;83(5):385-94. Bull Cancer. 1996. PMID: 8680091 Clinical Trial. French.
-
Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.Anticancer Drugs. 1993 Oct;4(5):577-83. doi: 10.1097/00001813-199310000-00008. Anticancer Drugs. 1993. PMID: 8292816
-
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.J Clin Oncol. 1994 Feb;12(2):360-7. doi: 10.1200/JCO.1994.12.2.360. J Clin Oncol. 1994. PMID: 8113844 Clinical Trial.
-
[Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].Nihon Yakurigaku Zasshi. 2000 Oct;116(4):215-23. doi: 10.1254/fpj.116.215. Nihon Yakurigaku Zasshi. 2000. PMID: 11084918 Review. Japanese.
-
Vinorelbine: a novel vinca alkaloid.Am J Health Syst Pharm. 1995 Jun 15;52(12):1287-304; quizz 1340-1. doi: 10.1093/ajhp/52.12.1287. Am J Health Syst Pharm. 1995. PMID: 7656116 Review.
Cited by
-
Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.Br J Cancer. 1998 Jun;77(11):1737-43. doi: 10.1038/bjc.1998.291. Br J Cancer. 1998. PMID: 9667641 Free PMC article.
-
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.Drugs Aging. 2002;19(9):695-721. doi: 10.2165/00002512-200219090-00006. Drugs Aging. 2002. PMID: 12381238 Review.
-
Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.Drugs Aging. 1994 Sep;5(3):200-34. doi: 10.2165/00002512-199405030-00006. Drugs Aging. 1994. PMID: 7803948 Review.
References
-
- ) Wiemann , M. C. and Calabresi , P.Pharmacology of antineoplastic agents . In “ Medical Oncology ,” ed. Calabresi P. , Schein P. S. and Rosenberg S. A. , pp. 327 – 329 ( 1985. ). Macmillan Publishing Company; , New York .
-
- ) Gralla , R. J. , Casper , E. S. , Kelsen , D. P. , Braun , D. W. , Jr. , Dukeman , M. E. , Martini , N. , Young , C. W. and Golbey , R. B.Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules . Ann. Intern. Med. , 95 , 414 – 420 ( 1981. ). - PubMed
-
- ) Kris , M. G. , Gralla , R. J. , Kalman , L.A. , Kelsen , D. P , Casper , E. S. , Burke , M. T. , Groshen , S. , Cibas , I. R. , Bagin , R. and Heelan , R. T.Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non‐small cell lung cancer, with an analysis of methods of response assessment . Cancer Treat. Rep. , 69 , 387 – 395 ( 1985. ). - PubMed
-
- ) Shinkai , T. , Saijo , N. , Tominaga , K. , Eguchi , K. , Shimizu , E. , Sasaki , Y. , Fujita , J. and Futami , H.Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non‐small cell lung cancer . Cancer Treat. Rep. , 69 , 945 – 951 ( 1985. ). - PubMed
-
- ) Ruckdeschel , J. C. , Finkelstein , D. M. , Ettinger , D. S. , Creech , R. H. , Mason , B. A. , Joss , R. A. and Vogl , S.A randomized trial of the four most active regimens for metastatic non‐small‐cell lung cancer . J. Clin. Oncol. , 4 , 14 – 22 ( 1986. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical